271 related articles for article (PubMed ID: 34165201)
21. Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies.
Dubinsky MC; DiBonaventura M; Fan H; Bushmakin AG; Cappelleri JC; Maller E; Thorpe AJ; Salese L; Panés J
Inflamm Bowel Dis; 2021 Jun; 27(7):983-993. PubMed ID: 32794567
[TBL] [Abstract][Full Text] [Related]
22. Presence of risk factors associated with colectomy among patients with ulcerative colitis: a
Rubin DT; Salese L; Cohen M; Kotze PG; Woolcott JC; Su C; Mundayat R; Paulissen J; Torres J; Long MD
Therap Adv Gastroenterol; 2023; 16():17562848231189122. PubMed ID: 37560161
[TBL] [Abstract][Full Text] [Related]
23. Modified Mayo score
Sandborn WJ; Sands BE; Vermeire S; Leung Y; Guo X; Modesto I; Su C; Wang W; Panés J
Therap Adv Gastroenterol; 2022; 15():17562848221136331. PubMed ID: 36506749
[TBL] [Abstract][Full Text] [Related]
24. Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials.
Feagan BG; Khanna R; Sandborn WJ; Vermeire S; Reinisch W; Su C; Salese L; Fan H; Paulissen J; Woodworth DA; Niezychowski W; Sands BE
Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1442-1453. PubMed ID: 34614208
[TBL] [Abstract][Full Text] [Related]
25. Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis.
Lichtenstein GR; Cohen BL; Salese L; Modesto I; Wang W; Chan G; Ahmed HM; Su C; Peyrin-Biroulet L
Dig Dis Sci; 2023 Jun; 68(6):2624-2634. PubMed ID: 36739367
[TBL] [Abstract][Full Text] [Related]
26. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
Mukherjee A; Hazra A; Smith MK; Martin SW; Mould DR; Su C; Niezychowski W
Br J Clin Pharmacol; 2018 Jun; 84(6):1136-1145. PubMed ID: 29377257
[TBL] [Abstract][Full Text] [Related]
27. Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain.
Allegretti JR; Gecse KB; Chiorean MV; Argollo M; Guo X; Lawendy N; Su C; Mundayat R; Paulissen J; Salese L; Irving PM
J Gastroenterol Hepatol; 2024 Feb; 39(2):264-271. PubMed ID: 37953548
[TBL] [Abstract][Full Text] [Related]
28. Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open.
Biedermann L; Dubinsky MC; Vermeire S; Fellmann M; Gardiner S; Hur P; Mundayat R; Panés J; Rubin DT
Inflamm Bowel Dis; 2023 Sep; 29(9):1370-1379. PubMed ID: 36242764
[TBL] [Abstract][Full Text] [Related]
29. Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program.
Dubinsky MC; Magro F; Steinwurz F; Hudesman DP; Kinnucan JA; Ungaro RC; Neurath MF; Kulisek N; Paulissen J; Su C; Ponce de Leon D; Regueiro M
Inflamm Bowel Dis; 2023 Jan; 29(1):51-61. PubMed ID: 35380664
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open.
Matsuoka K; Hisamatsu T; Kim HJ; Ye BD; Arai S; Hoshi M; Yuasa H; Tabira J; Toyoizumi S; Shi N; Woo JS; Hibi T
J Gastroenterol Hepatol; 2022 Oct; 37(10):1884-1892. PubMed ID: 35734858
[TBL] [Abstract][Full Text] [Related]
31. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials.
Panaccione R; Isaacs JD; Chen LA; Wang W; Marren A; Kwok K; Wang L; Chan G; Su C
Dig Dis Sci; 2021 Aug; 66(8):2732-2743. PubMed ID: 32816215
[TBL] [Abstract][Full Text] [Related]
32. Disease Activity and Health-related Quality of Life Relationships with Work Productivity in Patients with Ulcerative Colitis in OCTAVE Induction 1 and 2 and OCTAVE Sustain.
Targownik L; Dubinsky MC; Steinwurz F; Bushmakin AG; Cappelleri JC; Tai E; Gardiner S; Hur P; Panés J
J Crohns Colitis; 2023 Apr; 17(4):513-523. PubMed ID: 36271912
[TBL] [Abstract][Full Text] [Related]
33. Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program.
Lichtenstein GR; Bressler B; Francisconi C; Vermeire S; Lawendy N; Salese L; Sawyerr G; Shi H; Su C; Judd DT; Jones T; Loftus EV
Inflamm Bowel Dis; 2023 Jan; 29(1):27-41. PubMed ID: 36342120
[TBL] [Abstract][Full Text] [Related]
34. Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.
Lichtenstein GR; Rogler G; Ciorba MA; Su C; Chan G; Pedersen RD; Lawendy N; Quirk D; Nduaka CI; Thorpe AJ; Panés J
Inflamm Bowel Dis; 2021 May; 27(6):816-825. PubMed ID: 32766762
[TBL] [Abstract][Full Text] [Related]
35. Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies.
Mukherjee A; Tsuchiwata S; Nicholas T; Cook JA; Modesto I; Su C; D'Haens GR; Sandborn WJ
Clin Pharmacol Ther; 2022 Jul; 112(1):90-100. PubMed ID: 35380740
[TBL] [Abstract][Full Text] [Related]
36. Improvements in Disease Activity Partially Mediate the Effect of Tofacitinib Treatment on Generic and Disease-Specific Health-Related Quality of Life in Patients with Ulcerative Colitis: Data from the OCTAVE Program.
Dubinsky MC; Armuzzi A; Gecse KB; Ullman T; Bushmakin AG; DiBonaventura M; Cappelleri JC; Connelly SB; Woolcott JC; Salese L
Dig Dis; 2023; 41(4):604-614. PubMed ID: 36603566
[TBL] [Abstract][Full Text] [Related]
37. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
Panés J; Su C; Bushmakin AG; Cappelleri JC; Mamolo C; Healey P
BMC Gastroenterol; 2015 Feb; 15():14. PubMed ID: 25651782
[TBL] [Abstract][Full Text] [Related]
38. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.
Sandborn WJ; Panés J; Sands BE; Reinisch W; Su C; Lawendy N; Koram N; Fan H; Jones TV; Modesto I; Quirk D; Danese S
Aliment Pharmacol Ther; 2019 Nov; 50(10):1068-1076. PubMed ID: 31599001
[TBL] [Abstract][Full Text] [Related]
39. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
Winthrop KL; Melmed GY; Vermeire S; Long MD; Chan G; Pedersen RD; Lawendy N; Thorpe AJ; Nduaka CI; Su C
Inflamm Bowel Dis; 2018 Sep; 24(10):2258-2265. PubMed ID: 29850873
[TBL] [Abstract][Full Text] [Related]
40. Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme.
Schreiber S; Rubin DT; Ng SC; Peyrin-Biroulet L; Danese S; Modesto I; Guo X; Su C; Kwok KK; Jo H; Chen Y; Yndestad A; Reinisch W; Dubinsky MC
J Crohns Colitis; 2023 Nov; 17(11):1761-1770. PubMed ID: 37402275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
